iTeos Therapeutics与GSK价值20亿美元的TIGIT合作未达预期后将关闭公司iTeos Therapeutics to Shut Down After $2 Billion TIGIT Collaboration with GSK Falls Short

动脉网2025-05-29

by Mark Chiang马克·蒋Share To分享到iTeos Therapeutics has announced plans to cease operations following the failure of its TIGIT asset, which was developed in partnership with GSK. The company intends to ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2539269071?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-29 22:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2539269071","market":"us","top_or_hot":-1,"title":"iTeos Therapeutics与GSK价值20亿美元的TIGIT合作未达预期后将关闭公司iTeos Therapeutics to Shut Down After $2 Billion TIGIT Collaboration with GSK Falls Short","media":"动脉网","content":"<div>\n<p>by Mark Chiang马克·蒋Share To分享到iTeos Therapeutics has announced plans to cease operations following the failure of its TIGIT asset, which was developed in partnership with GSK. The company intends to ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505292208329769ea15&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iTeos Therapeutics与GSK价值20亿美元的TIGIT合作未达预期后将关闭公司iTeos Therapeutics to Shut Down After $2 Billion TIGIT Collaboration with GSK Falls Short</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niTeos Therapeutics与GSK价值20亿美元的TIGIT合作未达预期后将关闭公司iTeos Therapeutics to Shut Down After $2 Billion TIGIT Collaboration with GSK Falls Short\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-29 22:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505292208329769ea15&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by Mark Chiang马克·蒋Share To分享到iTeos Therapeutics has announced plans to cease operations following the failure of its TIGIT asset, which was developed in partnership with GSK. The company intends to ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505292208329769ea15&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505292208329769ea15&s=b","article_id":"2539269071","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505292208329769ea15&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2539269071","pubTimestamp":1748527560,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"The shutdown marks a significant development for iTeos, which had focused on advancing immuno-oncology therapies. The company partnered with GSK in 2021 to develop EOS-448, an anti-TIGIT monoclonal antibody designed to enhance immune system responses against cancer. Despite initial optimism surrounding the program, results failed to demonstrate sufficient efficacy or commercial viability.这一关闭标志着iTeos的一项重大进展，该公司此前专注于推进免疫肿瘤学疗法。2021年，该公司与GSK合作开发EOS-448，这是一种旨在增强免疫系统对癌症反应的抗TIGIT单克隆抗体。As part of its closure process, iTeos will prioritize shareholder payouts and seek buyers for its remaining pipeline assets..作为其关闭过程的一部分，iTeos将优先考虑股东分红，并为其剩余的管线资产寻找买家。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4532":"文艺复兴科技持仓","ITOS":"iTeos Therapeutics","GSK.UK":"葛兰素史克","LENZ":"Therapeutics","BK4007":"制药","GSK":"葛兰素史克","BK4588":"碎股","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"iTeos Therapeutics to close company after $2 billion TIGIT partnership with GSK misses expectations iTeos Therapeutics to Shut Down After $2 Billion TIGIT Collaboration with GSK Falls Short","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITOS":1,"LENZ":1,"GSK":1,"GSK.UK":0.6},"content_text":"by Mark Chiang马克·蒋Share To分享到iTeos Therapeutics has announced plans to cease operations following the failure of its TIGIT asset, which was developed in partnership with GSK. The company intends to distribute its remaining cash reserves to shareholders and liquidate proceeds from the sale of its pipeline assets. This decision comes after the TIGIT program, valued at $2 billion under the collaboration agreement, did not meet expectations..iTeos Therapeutics 宣布计划在与GSK合作开发的TIGIT资产失败后停止运营。公司打算将其剩余现金储备分配给股东，并通过出售其管线资产清算收益。这一决定是在该TIGIT项目未能达到预期后作出的，该项目在合作协议中估值达20亿美元。The shutdown marks a significant development for iTeos, which had focused on advancing immuno-oncology therapies. The company partnered with GSK in 2021 to develop EOS-448, an anti-TIGIT monoclonal antibody designed to enhance immune system responses against cancer. Despite initial optimism surrounding the program, results failed to demonstrate sufficient efficacy or commercial viability.这一关闭标志着iTeos的一项重大进展，该公司此前专注于推进免疫肿瘤学疗法。2021年，该公司与GSK合作开发EOS-448，这是一种旨在增强免疫系统对癌症反应的抗TIGIT单克隆抗体。尽管该项目初期充满乐观，但结果未能显示出足够的疗效或商业可行性。As part of its closure process, iTeos will prioritize shareholder payouts and seek buyers for its remaining pipeline assets..作为其关闭过程的一部分，iTeos将优先考虑股东分红，并为其剩余的管线资产寻找买家。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1Date: May 29, 2025日期：2025年5月29日Related posts:相关文章:Pharma M&A Deal Value Drops 46.9% in March 2025: GlobalData Report2025年3月医药并购交易额下降46.9%：GlobalData报告Latin America Generic Drug Market Growth Threatened by Regulatory Hurdles Despite Rising Demand for Affordable Healthcare拉丁美洲仿制药市场增长受到监管障碍的威胁，尽管对可负担医疗保健的需求不断上升Pharmacists Guide Gene Therapy Patients: Expertise Ensures Safer Outcomes and Medication Management.药剂师指导基因治疗患者：专业知识确保更安全的结果和药物管理。Global Generic Drug Market Projected to Reach $1.2 Trillion by 2028.全球仿制药市场预计到2028年将达到1.2万亿美元。©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 保留所有权利。与我们合作：[email protected][email protected]Author作者Mark Chiang马克·蒋Related Post相关内容News Flash新闻快讯HHS Ends Moderna Vaccine Contract as FDA Rejects Rare Disease DrugHHS终止Moderna疫苗合同，因FDA拒绝罕见病药物2025-05-292025年5月29日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2539269071","isCrawlerRequest":true}